Cockroaches, Rats and Mice: These Are the Country’s Most Infested Cities
New York really is the most infested city in the country, at least according to a Bloomberg analysis of Census Bureau data on cockroach, mouse and rat sightings.
The Big Apple doesn’t lead in any of those individual categories. Homes in Tampa, Fla., have the most roaches, and those in Seattle may have the most rats. Philadelphia houses had the most mouse sightings in the country. But when Bloomberg combined all three categories, New York came out with the highest cumulative score.
Perhaps surprising given the economic state of the city, Detroit residents were the least likely to report seeing a mouse, rat or roach.
Related: The Top 9 Summer Insects to Avoid and How
The data covered only 25 metro areas, so some large cities like Dallas, Los Angeles and San Francisco don’t appear on the list.
Roaches appear to enjoy nice weather. Nearly 40 percent of homes in Tampa had evidence in roaches in the past year, followed by Houston and Austin. Cities with the fewest roach sightings were Seattle, Minneapolis and Detroit.
Mice, on the other, hand, seem to prefer the northeast. Nearly 20 percent of Philly homes had evidence of mice, followed by Baltimore and Boston. Tampa, Jacksonville, and Las Vegas had the lowest percentage of mouse sightings.
More than 20 percent of homes in Seattle and Austin had rats, with Miami rounding out the top three. Richmond, Va., Hartford, Conn., and Minneapolis had the lowest level of rat sightings.
All those vermin lead to big business. Last year, the U.S. pest control industry generated nearly $7.5 billion in revenue, a 3.5 percent increase year-over-year.
Bloomberg reported that the data also showed a difference in infestation levels of homes with families living below the poverty line and minority families, which were more likely to report evidence of rats and roaches.
Top Reads from The Fiscal Times:
- Cecil the Lion Gives Voice to a Growing List of Illegal Slaughters
- How the Media and You Are Misled by False Data
- America’s 10 Top Selling Medications
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
